Cerity Partners
LXEO icon

Cerity Partners’s Lexeo Therapeutics LXEO Stock Holding History

Cerity Partners’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.8K Sell
13,911
-7,116
-34% -$38.5K ﹤0.01% 3274
2026
Q1 		$121K Sell
21,027
-1,412
-6% -$10K ﹤0.01% 2996
2025
Q4 		$223K Sell
22,439
-1,151
-5% -$10.5K ﹤0.01% 2577
2025
Q3 		$157K Buy
23,590
+11,143
+90% +$53.9K ﹤0.01% 2555
2025
Q2 		$50K Buy
+12,447
New +$40.9K ﹤0.01% 2546

Other funds holding LXEO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JTL
Jupiter Topco LLC New York $245B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Cerity Partners's LXEO Position: Q2 2026 in Review

Cerity Partners reduced its Lexeo Therapeutics (LXEO) stake by 34% in Q2 2026, selling an estimated $38.5K and leaving 13,911 shares worth $64.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3274.

Cerity Partners first reported a position in LXEO in Q2 2025 and has held it in 5 quarters since. The position peaked at $223K in Q4 2025. 132 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Cerity Partners held 13,911 shares of Lexeo Therapeutics worth $64.8K as of Q2 2026.
  • Cerity Partners sold 7,116 Lexeo Therapeutics shares in Q2 2026, an estimated $38.5K.
  • Lexeo Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3274 holding.
  • Cerity Partners first reported a position in Lexeo Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Cerity Partners's Lexeo Therapeutics position peaked at $223K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.